Eurofins Genomics Blue Heron, a provider of DNA synthesis, sequencing services, and gene synthesis, launched its cutting-edge IVT mRNA Synthesis Service. With the service, the company aims to offer a game-changing solution to the challenges of gene expression research.

The new service offers a comprehensive solution for researchers seeking high-quality, customizable mRNA synthesis with fast turnaround times. The IVT mRNA Synthesis Service is based on the latest in vitro transcription (IVT) technology, which allows for the rapid and efficient synthesis of high-quality messenger RNA (mRNA) transcripts.

According to the company, the IVT mRNA Synthesis Service has been designed to meet the needs of scientists in a wide range of fields, including molecular biology, drug discovery, vaccine development, and gene therapy. The service will allow researchers to customize mRNA transcripts to suit their specific research needs, including modifying the sequence, length, and purity of the mRNA.

The IVT mRNA Synthesis Service offers:

• High-quality mRNA synthesis for a wide range of applications
• Fast turnaround times and delivery options
• Customizable mRNA synthesis to meet specific research needs
• Competitive pricing to fit all budgets
• A dedicated team of experts to assist with all aspects of the synthesis process

“We are excited to offer this groundbreaking service to the scientific community,” said Isaiah Chuang, president of Eurofins Genomics Blue Heron. “Our IVT mRNA Synthesis Service is a game-changer for researchers seeking to advance their work in gene expression research, drug discovery, and beyond. We look forward to partnering with researchers to help them achieve their goals.”